World Health Organization Warehouse Pharmaceutical Import Profile — United Arab Emirates (DGFT 2022–2026)

Name: World Health Organization Warehouse Pharmaceutical Import Records from India — 2 Products, $504.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

World Health Organization Warehouse — Pharmaceutical Importer Profile (2026) | 2 Products, $504.0K Trade | TransData Nexus

World Health Organization Warehouse

Pharmaceutical Importer · United Arab Emirates · Other Focus · $504.0K Total Trade · DGFT Verified

World Health Organization Warehouse is a pharmaceutical importer based in United Arab Emirates with a total trade value of $504.0K across 2 products in 2 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. World Health Organization Warehouse sources from 12 verified Indian suppliers, with Galentic Pharma India Private Limited accounting for 24.8% of imports.

World Health Organization Warehouse — Import Portfolio & Supplier Network

World Health Organization Warehouse import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to World Health Organization Warehouse?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Galentic Pharma India Private Limited	$341.5K	7	24.8%
Premium Serums And Vaccines Private Limited	$280.2K	8	20.4%
Msn Laboratories Private Limited

What Formulations Does World Health Organization Warehouse Import?

Formulation	Value	Ships
Harmless medicines zinc oxide ointment 10%, 100g (zinc oxide ointment 10%)	$245.2K	5
Diphtheria antitoxin IP 10000iu/10ML	$198.7K	6
Harmless medicines zinc oxide ointment 10 100g zinc oxide ointment	$96.3K	2
Amphonex 50MG (lyop) liposomal	$50.0K	1
Sunitinib 50 MG 1x28s aurugulf	$50.0K	1
Pomalidomide 4MG 1x21 s aurugulf	$50.0K	1
Sunitinib 12 5MG 1x28s aurugulf	$50.0K	1
[other medicaments - erythropoietin] erythropoietin injection - repoitin 4000 IU, recombinant	$50.0K	1
Diphtheria antitoxin IP	$50.0K	1
Human medicine-ringer lactate, 500 ML, plastic bottle,?w/ iv giving set? 500 ML(1 x 24 bottles)	$50.0K	1
Diphtheria antitoxin IP 10000iu liquid 10ML in	$49.9K	1
Pomalidomide 2MG 1x21 s aurugulf	$45.4K	1
Diphtheria antitoxin IP 10000iu/10ML (lyophilized enzyme refined equine immunoglobulins)	$42.8K	2
Amoxicillin and clavulanate potassium for oral suspension USP 312 5MG 5ML 40085 x 100ML	$42.5K	1
Human medicine-0.45% w/v sodium chlorideand 5% w/v glucose intravenous infusionbp 500ML eurohead(1x24 bottles)	$40.0K	3

World Health Organization Warehouse imports 32 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Antitoxin	Other	$404.0K	10	3.0%	7
2	Pomalidomide	Advanced Oncology	$100.0K	2	2.3%	5

World Health Organization Warehouse imports 2 pharmaceutical products across 2 categories into United Arab Emirates totaling $504.0K.

World Health Organization Warehouse — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The World Health Organization Warehouse (WHO Warehouse) is a pharmaceutical importer and buyer based in the United Arab Emirates (UAE). As a medical warehouse, it is licensed to store and possess medical products and pharmaceutical raw materials, and may also be authorized for import, distribution, re-export, or other activities as determined by the UAE's Executive Regulations. (uaelegislation.gov.ae) The WHO Warehouse plays a pivotal role in the UAE's pharmaceutical distribution network, ensuring the availability of essential medical products to meet the country's healthcare needs.

2Distribution Network

While specific details about the WHO Warehouse's distribution network are not publicly disclosed, as a licensed medical warehouse in the UAE, it is authorized to import, store, and distribute medical products. This includes the capacity to re-export products, facilitating a comprehensive logistics operation that serves both domestic and international markets. The warehouse's strategic location within the UAE enables efficient distribution across the country and potentially to neighboring regions, leveraging the UAE's advanced infrastructure and connectivity.

3Industry Role

In the UAE's pharmaceutical supply chain, the WHO Warehouse functions primarily as a medical warehouse. It is licensed to store and possess medical products and pharmaceutical raw materials, and may also be authorized for import, distribution, re-export, or other activities as determined by the UAE's Executive Regulations. (uaelegislation.gov.ae) This role is crucial in ensuring the availability and distribution of medical products within the UAE, supporting both public and private healthcare sectors.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — World Health Organization Warehouse

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The WHO Warehouse's sourcing strategy exhibits a high degree of concentration, with its top five products accounting for 100% of its imports from India. This indicates a strategic focus on specific high-value products, notably antitoxin and pomalidomide, which together constitute the majority of the import value. Such concentration can streamline procurement processes and strengthen supplier relationships. However, it also introduces risks associated with dependency on a limited number of products and suppliers. The shipment data reveals a stable relationship with key suppliers, as evidenced by multiple shipments from each, suggesting a reliable supply chain. Nonetheless, the absence of diversification in product sourcing may expose the WHO Warehouse to supply chain disruptions if any of these key products face production or regulatory challenges.

2Supply Chain Resilience

The WHO Warehouse's supply chain resilience is closely tied to its sourcing strategy. With a concentrated focus on a limited number of products and suppliers, the warehouse's supply chain may be vulnerable to disruptions affecting these key items. The lack of backup suppliers for its top products indicates a potential risk in maintaining uninterrupted supply. Additionally, the diversity of formulations imported suggests a degree of flexibility in meeting various medical needs. However, the heavy reliance on specific products and suppliers underscores the importance of developing contingency plans and diversifying sourcing strategies to enhance supply chain resilience.

Importing Pharmaceuticals into United Arab Emirates — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Arab Emirates

1Regulatory Authority & Framework

The UAE's pharmaceutical sector is governed by the Emirates Drug Establishment (EDE), which oversees the import, distribution, and regulation of medical products. The Federal Decree-Law No. 8 of 2019 on Medical Products, Pharmacy Profession, and Pharmaceutical Facilities provides the legal framework for pharmaceutical activities in the UAE. This legislation outlines the responsibilities of pharmaceutical establishments, including medical warehouses, and sets forth the procedures for obtaining approvals and permits for importing, exporting, and distributing medical products. The EDE's role is to ensure the safety, efficacy, and quality of medical products circulating within the UAE. (uaelegislation.gov.ae)

2Import Licensing & GMP

Import licensing in the UAE requires pharmaceutical establishments to obtain approvals from the EDE for each shipment of medical products. This process ensures that imported products meet the UAE's regulatory standards. The EDE recognizes Good Manufacturing Practice (GMP) certifications from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical establishments must ensure that their suppliers hold valid GMP certifications to comply with UAE regulations. Additionally, wholesale distribution authorization is required for entities involved in the distribution of medical products within the UAE. (uaelegislation.gov.ae)

World Health Organization Warehouse — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

The WHO Warehouse's focus on importing antitoxin and pomalidomide suggests a strategic emphasis on critical therapeutic areas. Antitoxins are essential for treating various poisoning cases, while pomalidomide is a key medication in advanced oncology treatments. The market demand for these products is driven by the UAE's healthcare needs, particularly in managing acute poisoning incidents and providing advanced cancer therapies. By concentrating on these therapeutic areas, the WHO Warehouse aligns its product strategy with the pressing medical requirements of the UAE population.

2Sourcing Profile

The WHO Warehouse's sourcing strategy is centered on high-value generic drugs, specifically antitoxin and pomalidomide. The diversity of formulations imported indicates a preference for a range of delivery forms to meet various patient needs. India's role as a supplier is significant, given its capacity to produce high-quality generic medications that meet international standards. The WHO Warehouse's procurement strategy likely involves evaluating suppliers based on product quality, regulatory compliance, and the ability to meet specific therapeutic demands.

3Market Positioning

Seller's Guide — How to Become a Supplier to World Health Organization Warehouse

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with the WHO Warehouse, particularly if they can offer high-quality products that align with the warehouse's focus on critical therapeutic areas. Gaps in the WHO Warehouse's current sourcing may include the need for additional suppliers to diversify its supply base and mitigate potential risks associated with over-reliance on a limited number of products and suppliers. Indian exporters can explore these opportunities by ensuring their products meet the UAE's regulatory standards and by establishing strong relationships with the WHO Warehouse.

2Requirements & Qualifications

Indian exporters aiming to supply the WHO Warehouse must ensure that their products comply with the UAE's regulatory standards, including holding valid GMP certifications recognized by the EDE. They must also adhere to the UAE's import licensing requirements, which involve obtaining approvals from the EDE for each shipment. Additionally, products must meet quality and labeling standards, including batch testing, stability requirements, and labeling in both Arabic and English. Serialization mandates must also be followed to facilitate tracking and monitoring of products throughout the supply chain. (uaelegislation.gov.ae)

Frequently Asked Questions — World Health Organization Warehouse

What products does World Health Organization Warehouse import from India?

World Health Organization Warehouse imports 2 pharmaceutical products across 2 categories. Top imports: Antitoxin ($404.0K), Pomalidomide ($100.0K).

Who supplies pharmaceuticals to World Health Organization Warehouse from India?

World Health Organization Warehouse sources from 12 verified Indian suppliers. The primary supplier is Galentic Pharma India Private Limited (24.8% of imports, $341.5K).

What is World Health Organization Warehouse's total pharmaceutical import value?

World Health Organization Warehouse's total pharmaceutical import value from India is $504.0K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does World Health Organization Warehouse focus on?

World Health Organization Warehouse imports across 2 categories. The largest: Other (80.2%), Advanced Oncology (19.8%).

Get Full World Health Organization Warehouse Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.